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Abstract:
BACKGROUND: In this paper, we evaluate the therapeutic and
adverse effects of the application of 166-holmium-boro-macro-
aggregates (HMBA) in radiosynovectomy (RSO) of the knees.
We assessed the efficacy and safety of 166Ho-HBMA in a pros-
pective clinical trial in patients suffering from chronic synovitis.
MATERIAL AND METHODS: An effective component of radiop-
harmaceutical 166Ho-boro-macroaggregates is radionuclide
166Ho which has both  b-emission and g-emission. The physical
half-life time of 166Ho is 26.8 hours. After application of the ra-
diopharmaceutical into a joint cavity, the effect of  b-emission
causes radiation necrosis of pathologically changed (inflamed)
synovial membrane. From 15th April 2005, we have started RSO
of knees by means of new radiopharmaceutical 166Ho-boro-mac-
roaggregates in patients with gonarthrosis, rheumatoid arthri-
tis, chronic synovitis, psoriatic arthritis, gout arthropathy. Seven-
teen intra-articular injections were performed in fifteen patients
receiving a mean activity of 972 MBq (range: 9041057 MBq)
166Ho-HMBA. The patients were hospitalized for three days. Side
effects were evaluated during hospital stay and after 68 weeks.
Static scintigraphy of knee joints and measurements of blood
radioactivity were performed. Therapeutic effects were evaluat-
ed after 68 weeks.
RESULTS: In 2 hours and 2 days after application, we proved,
by means of knee and inguinal scintigraphy, only insignificant
radiopharmaceutical leakage from the joint cavity to the inguinal
lymph nodes in four patients. In treated patients, no serious
adverse effects occurred. Nine patients were without complaints;
4 patients had slight knee exsudation and 2 patients had great
exsudation. Therapeutic effects after 68 weeks were as fol-
lows: 2 patients  were without pain, 9 with lower pain, 3 with the
same pain and 1 patient with increased pain. Joint motion was
improved in 7 patients, remained the same in 7 patients and
was impaired in 1 patient. Analgesics consumption was lower
in 5 patients, the same in 9 patients and greater in 1 patient.
Knee exsudation was absent in 2 patients, lower in 4 patients,
the same in 6 patients and greater in 3 patients.
CONCLUSIONS: We proved only insignificant radiopharmaceu-
tical leakage from the joint cavity to the inguinal lymph nodes.
Six patients had early slight or great radiation synovitis. The
possible cause could be rather high applicated activity. One
can take into consideration its reduction. Therapeutic effects
can be precisely evaluated after a longer time interval than was
possible for us (68 weeks after RSO). 166Ho-boro-macro-
aggregates can extend the scale of clinically used radiophar-
maceuticals for RSO.
This paper is presented in the scope of the first stage of clinical
evaluation of synovectomy application of holmium-boro-macro-
aggregates.
Key words: radiosynoviorthesis, radiation synovectomy,
radionuclide synovectomy, holmium-166, 166Ho-boro-macro-
aggregates, adverse effects, therapeutic effects, chronic
synovitis
Introduction
We present our first experiences with radiosynovectomy
(RSO) of knees utilising 166Ho-boro-macroaggregates (HMBA).
We evaluated the adverse and therapeutic effects of applied
HMBA in a prospective clinical trial in patients suffering from
chronic synovitis.
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Material and methods
166Ho-HMBA Preparation
Radiopharmaceutical 166Ho-boro-macroaggregates have
been produced in the Nuclear Physics Institute of the Czech
Academy of Science in Ře, near Prague, Czech Republic [1].
Main production steps of 166Ho-boro-macroaggregates are
shown in Table 1. The structure of Ho-macroaggregates is
shown in Figure 1, and the spectrum of microsphere size distri-
bution in Figure 2. Organ biodistribution studies with 166Ho-boro-
macroaggregates were carried out in rats [1]; the results are
shown in Table 2. Patients and procedure
On 15th April 2005, we started RSO of the knees by means of
a new radiopharmaceutical, 166Ho-boro-macroaggregates. All pa-
tients gave their informed consent to the treatment protocol. We
treated 17 knees in 15 patients with chronic synovitis (8 men,
7 women, average age 49.6 yrs; seven patients with gonarthrosis,
6 patients with rheumatoid arthritis, one patient with psoriatic
arthritis and one patient with gout arthropathy) with a mean ac-
tivity of 972 MBq (range: 9041057 MBq) of 166Ho-HMBA. Pa-
tients inclusion to the study was based upon criteria shown in
Table 3. The patients were hospitalized for 3 days. Adverse ef-
fects were evaluated during hospitalization and after 68 weeks.
Scintigraphy of knee joints was done at 2 and 48 hours after
RSO by means of dual-head SPECT camera E.CAM (Siemens,
Erlangen, Germany). Scans were performed in anterior and pos-
terior projections of knees and inguinal areas, 5 minutes acqui-
sition time per projection. Measurements of blood radioactivity
were performed 4 and 24 hours after RSO (activity of 1 ml of
blood measured in a well scintillation detector). Therapeutic
effects were evaluated after 68 weeks. The project had the
approval of the Local Ethical Committee.
Results
Radiopharmaceutical leakage
Two hours after application, we observed a homogenous distri-
bution of radiopharmaceutical in the knee cavity on scintigrams (Fi-
gure 3) and we did not prove any accumulation in the inguinal lymph
nodes. Two days after application, we proved only insignificant ra-
diopharmaceutical accumulation in the inguinal lymph nodes in four
patients (leakage accounted to < 1% of the total activity) (Figure 4).
In 11 patients, no leakage was detected (Figure 5).
Blood activity
Activity measurement in 1 millilitre of blood, 4 hours after ap-
plication, was 1021802 counts/minute, average 650 counts/min.
24 hours after application it was 561079 counts/min, average
443 counts/min.
Side effects
In our group of patients no serious unwanted effects occurred.
Nine patients were without complaints, 4 patients had slight knee
exsudation and 2 patients had great knee exsudation.
Treatment effect
Therapeutic effects after 68 weeks were as follows: 2 pa-
tients were without pain, 9 with lower pain, 3 with the same pain
Table 2. Organ radioactivity measurement in rats
Organ Radioactivity
Blood 0.001%
Lung 0.003%
Spleen 0.001%
Kidney 0.001%
Liver 0.033%
Left knee joint 99.961%
Table 1. Main production steps of 166Ho-macroaggregates
1. Preparation of non-radioactive Ho-macroaggregates particles
Reaction of the Ho(NO3)3 solution with the NaBH4 in 0.2 M NaOH
Washing and drying of precipitated particles
Milling & micro sieving
2. Irradiation in the nuclear reactor
3. Preparation of particles suspension in saline (0.9% NaCl solution)
4. Steam sterilisation
5. Distribution to the hospital
Radionuclide purity > 99%                    Radiochemical purity > 90%
Figure 1. Structure of Ho-macroaggregates. Electron microscope scan:
particles before sieving, inorganic compound, 5060%w of Ho incorporated.
Figure 2. Structure of Ho-macroaggregates. Laser Particle Size Analyser
CILAS: spectrum of microspheres size distribution in suspension after
sieving.
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Table 3. Inclusion and exclusion criterions
Inclusion criterions Exclusion criterions
Age 1860 years Drug allergy
Joint affections: Gravidity, lactation
RA Infection or febrile conditions last 4 weeks
Osteoarthrosis Infectious knee or bone affections
Psoriatic arthropathy Knee RSO last 6 months
Other X-ray knee irradiation last 6 months
Repeated hydrops Intra-articular knee application of corticoids last 2 months
Informed consent Significant destruction of knee
Positive HIV, HCV, HBsAg
Significant deviation of laboratory tests
Participation in other clinical study last 6 months
Inability of co-operation
Foreigner
Disabled patient
Person performed military service or in prison
Figure 3. Distribution of radiopharmaceutical in knee cavity after 2 hours
after RSO.
and 1 patient with increased pain. Joint motion was improved in
7 patients, unchanged in 7 patients and impaired in one patient.
Analgesic consumption was lower in 5 patients, the same in
9 patients and greater in one patient. Knee exsudation totally with-
drew in 2patients, was decreased in 4 patients,  was the same in
6 patients and greater in 3 patients
Discussion
Radiation synovectomy (RSO) by intra-articular injection
of beta-emitting radionuclides is a reliable and easy-to-per-
form therapy without harmful side effects for the treatment of
inflammatory rheumatoid, as well as degenerative, joint dis-
eases. The indication for radiation synovectomy is based on
Figure 4. 48 hours after application: distribution of radiopharmaceutical
in knee cavity and insignificant radiopharmaceutical leakage from the
joint cavity to the inguinal lymph nodes.
Figure 5. 48 hours after application: distribution of radiopharmaceutical
in knee cavity without leakage to the inguinal lymph nodes.
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both clinical symptoms and on proven hyperperfusion, with
active synovitis being seen on a pre-treatment three-phase
bone scan.
Radiation synovectomy is the alternative way for surgical
synovectomy. It is possible to repeat this therapy with similarly
good results as the first therapy [2]. The most often used radiop-
harmaceuticals are colloids labelled with 90Y [3] or 32P [4] (for big
joints  knees), 186Re (for medium joints) [5] and 169Er (for small
joints) [6]. In addition to these colloids, there are many other ra-
diopharmaceuticals suitable for RSO (Table 4) [710].
An effective component of 166Ho-boro-macroaggregates is ra-
dionuclide 166Ho, which has b-emission with maximum energy of
1.85 MeV, maximum soft tissue penetration of 8.7 millimetres and g
emission of energy 4858 keV (9.8%), 81 keV (6.2%) and in small
proportion 1379 keV. The physical half-life time of 166Ho is 26.8 hours.
Its daughter nuclide is 166Eu (Europium) which is stable. The hol-
mium-166 was prepared in a LWR-15 nuclear reactor (810 MW)
by 165Ho (n, g) 166Ho reaction (neutron flux 10131014 neutrons.cm-
24.s-1) [1]. After an application of the radiopharmaceutical to the joint
cavity, the micro-particles, which are carriers of radionuclides, are
trapped by macrophages and transported to the synovia, then the
effect of b-emission causes radiation necrosis of the pathologically
changed (inflamed) synovial membrane.
Conclusions
We proved only insignificant radiopharmaceutical leakage from
the joint cavity to the inguinal lymph nodes.  Blood activity after
4 and 24 hours was not significant. Six patients had early slight or
great radiation synovitis; the possible cause could be the rather
high activity applied (in average 972 MBq). One can take into con-
sideration its reduction. Therapeutic effects can be precisely evalu-
ated after a longer time interval than was available to us (68 weeks
after RSO). We have planned to treat other patients with reduced
activity (about 500 MBq) to decrease early adverse effects.
166Ho-holmium-boro-macroaggregates can extend the scale
of clinically used radiopharmaceuticals for RSO and fill the gap
between 90Y with high b-energy and 186Re a 169Er with lower ener-
gy. Energy of 166Ho is suitable for large and medium joints (knees,
hips, shoulders, elbows, wrists, ankles). It is also a prospective
agent for RSO because 166Ho is a radionuclide suitable for ima-
ging with a gamma camera after administration to the joints.
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Table 4. Radiopharmaceuticals for RSO
Radiopharmaceuticals Radionuclide
FHMA 166Ho, 165Dy, 169Er
Hydroxyapatit particles 166Ho, 186Re, 153Sm
Glass microspheres 90Y, 166Ho, 153Sm
Ho-B-MA 166Ho
Ho-PLA-MS 166Ho
Ho-citrate colloids 166Ho
HSA microspheres 186Re
Chitosan complex 166Ho, 165Dy, 169Er, 153Sm
FHMA  ferric hydroxid macroaggregates; Ho-B-MA  Ho-boro-macroaggregates; Ho-PLA-MS  Ho-polylactic acid microspheres
